drugset / Trial / NCT05909241
A Study of BA1202 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm phase I study in patients with advanced solid tumors which consists of a dose escalation part (Part A) and a dose extension part (Part B). Part A aims to evaluate the safety and tolerability of BA1202, and determine the MTD. Part B will also evaluate the preliminary efficacy of BA1202.
Timeline
- Start
- 2023-08-16
- Primary completion
- 2025-02
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BA1202 | Unknown | 0.016 mg | Intravenous |
| Subject | BA1202 | Unknown | 0.08 mg | Intravenous |
| Subject | BA1202 | Unknown | 0.4 mg | Intravenous |
| Subject | BA1202 | Unknown | 1.6 mg | Intravenous |
| Subject | BA1202 | Unknown | 6.4 mg | Intravenous |
| Subject | BA1202 | Unknown | 19 mg | Intravenous |
| Subject | BA1202 | Unknown | 38 mg | Intravenous |
| Subject | BA1202 | Unknown | 56 mg | Intravenous |